SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pasquini Marcelo)
 

Sökning: WFRF:(Pasquini Marcelo) > Effect of Condition...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005010naa a2200853 4500
001oai:DiVA.org:uu-374009
003SwePub
008190117s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:140781150
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3740092 URI
0247 a https://doi.org/10.1016/j.bbmt.2018.11.0052 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1407811502 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Brunstein, Claudio G4 aut
2451 0a Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
264 1b Elsevier BV,c 2019
338 a print2 rdacarrier
520 a Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥ 20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a Autologous hematopoietic cell transplantation
653 a Conditioning regimen
653 a Obesity
7001 a Pasquini, Marcelo C4 aut
7001 a Kim, Soyoung4 aut
7001 a Fei, Mingwei4 aut
7001 a Adekola, Kehinde4 aut
7001 a Ahmed, Ibrahim4 aut
7001 a Aljurf, Mahmoud4 aut
7001 a Agrawal, Vaibhav4 aut
7001 a Auletta, Jeffrey J4 aut
7001 a Battiwalla, Minoo4 aut
7001 a Bejanyan, Nelli4 aut
7001 a Bubalo, Joseph4 aut
7001 a Cerny, Jan4 aut
7001 a Chee, Lynette4 aut
7001 a Ciurea, Stefan O4 aut
7001 a Freytes, Cesar4 aut
7001 a Gadalla, Shahinaz M4 aut
7001 a Gale, Robert Peter4 aut
7001 a Ganguly, Siddhartha4 aut
7001 a Hashmi, Shahrukh K4 aut
7001 a Hematti, Peiman4 aut
7001 a Hildebrandt, Gerhard4 aut
7001 a Holmberg, Leona A4 aut
7001 a Lahoud, Oscar B4 aut
7001 a Landau, Heather4 aut
7001 a Lazarus, Hillard M4 aut
7001 a de Lima, Marcos4 aut
7001 a Mathews, Vikram4 aut
7001 a Maziarz, Richard4 aut
7001 a Nishihori, Taiga4 aut
7001 a Norkin, Maxim4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)4 aut0 (Swepub:uu)riols677
7001 a Reshef, Ran4 aut
7001 a Rotz, Seth4 aut
7001 a Savani, Bipin4 aut
7001 a Schouten, Harry C4 aut
7001 a Seo, Sachiko4 aut
7001 a Wirk, Baldeep M4 aut
7001 a Yared, Jean4 aut
7001 a Mineishi, Shin4 aut
7001 a Rogosheske, John4 aut
7001 a Perales, Miguel-Angel4 aut
7102 a Uppsala universitetb Centrum för klinisk forskning i Sörmland (CKFD)4 org
7730 t Biology of blood and marrow transplantationd : Elsevier BVg 25:3, s. 480-487q 25:3<480-487x 1083-8791x 1523-6536
8564 u http://www.bbmt.org/article/S1083879118306992/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374009
8564 8u https://doi.org/10.1016/j.bbmt.2018.11.005
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:140781150

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy